CorMedix Inc. (FRA:19KA)

CorMedix Statistics

Total Valuation

CorMedix has a market cap or net worth of EUR 664.87 million. The enterprise value is 745.04 million.

Market Cap	664.87M
Enterprise Value	745.04M

Important Dates

The next estimated earnings date is Wednesday, March 25, 2026.

Earnings Date	Mar 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	78.79M
Shares Outstanding	n/a
Shares Change (YoY)	+24.69%
Shares Change (QoQ)	+19.88%
Owned by Insiders (%)	6.85%
Owned by Institutions (%)	55.39%
Float	73.39M

Valuation Ratios

The trailing PE ratio is 4.80 and the forward PE ratio is 3.44.

PE Ratio	4.80
Forward PE	3.44
PS Ratio	3.64
PB Ratio	2.09
P/TBV Ratio	n/a
P/FCF Ratio	10.48
P/OCF Ratio	10.41
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.99, with an EV/FCF ratio of 11.75.

EV / Earnings	5.38
EV / Sales	4.04
EV / EBITDA	7.99
EV / EBIT	8.33
EV / FCF	11.75

Financial Position

The company has a current ratio of 1.94, with a Debt / Equity ratio of 0.40.

Current Ratio	1.94
Quick Ratio	1.60
Debt / Equity	0.40
Debt / EBITDA	1.37
Debt / FCF	2.00
Interest Coverage	106.62

Financial Efficiency

Return on equity (ROE) is 75.08% and return on invested capital (ROIC) is 22.31%.

Return on Equity (ROE)	75.08%
Return on Assets (ROA)	15.68%
Return on Invested Capital (ROIC)	22.31%
Return on Capital Employed (ROCE)	16.84%
Revenue Per Employee	2.81M
Profits Per Employee	2.13M
Employee Count	65
Asset Turnover	0.52
Inventory Turnover	0.69

Taxes

Income Tax	-47.27M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.83% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-11.83%
50-Day Moving Average	9.31
200-Day Moving Average	9.71
Relative Strength Index (RSI)	40.28
Average Volume (20 Days)	337

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	5.27

Income Statement

In the last 12 months, CorMedix had revenue of EUR 182.65 million and earned 138.50 million in profits. Earnings per share was 1.92.

Revenue	182.65M
Gross Profit	172.25M
Operating Income	88.60M
Pretax Income	91.23M
Net Income	138.50M
EBITDA	92.22M
EBIT	88.60M
Earnings Per Share (EPS)	1.92

Balance Sheet

The company has 47.49 million in cash and 126.93 million in debt, giving a net cash position of -79.44 million.

Cash & Cash Equivalents	47.49M
Total Debt	126.93M
Net Cash	-79.44M
Net Cash Per Share	n/a
Equity (Book Value)	318.87M
Book Value Per Share	4.07
Working Capital	107.30M

Cash Flow

In the last 12 months, operating cash flow was 63.90 million and capital expenditures -468,565, giving a free cash flow of 63.43 million.

Operating Cash Flow	63.90M
Capital Expenditures	-468,565
Free Cash Flow	63.43M
FCF Per Share	n/a

Margins

Gross margin is 94.31%, with operating and profit margins of 48.51% and 75.83%.

Gross Margin	94.31%
Operating Margin	48.51%
Pretax Margin	49.95%
Profit Margin	75.83%
EBITDA Margin	50.49%
EBIT Margin	48.51%
FCF Margin	34.73%

Dividends & Yields

CorMedix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.69%
Shareholder Yield	-24.69%
Earnings Yield	20.83%
FCF Yield	9.54%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on March 26, 2019. It was a reverse split with a ratio of 0.2.

Last Split Date	Mar 26, 2019
Split Type	Reverse
Split Ratio	0.2

Scores

CorMedix has an Altman Z-Score of 1.74 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.74
Piotroski F-Score	5